AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01272830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatone®B
Description: Two capsules taken twice daily with meals
Study NCT01336075 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous radiofrequency catheter ablation
Description: Percutaneous radiofrequency catheter ablation around the rights and lefts pulmonary veins, with complete circumferential ablation.
Study NCT01336075 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mini invasive thoracoscopic radiofrequency ablation
Description: Video-assisted thoracoscopic approach for electrical isolation of the pulmonary veins bilaterally and left atrial appendage excision or exclusion.
Study NCT02478242 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nafamostat mesilate
Description: nafamostat mesilate use for anticoagulation
Study NCT02478242 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Study NCT05442944 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physiotherapeutic procedures
Description: As part of the rehabilitation program, the patients performed two exercises in the Universal Therapeutic Rehabilitation Room (UTRR) system. The patient's task was to perform simultaneous abduction and adduction of the upper and lower limbs. The duration of the procedure was 10 minutes, the patient performed the exercises at a comfortable pace. In the second exercise - the patient's task was to alternately bend and straighten the opposite lower and upper limbs. The duration of the exercise was 10 minutes. The combined duration of both procedures used was 20 minutes. In addition, each patient underwent three physical therapy treatments. The procedures were carried out 5 days a week (Monday to Friday) for three weeks.
Study NCT03171987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine patch local application
Description: Attach the patch to back pain area 1 piece per day with no more than 6 hours.
Study NCT03171987 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flurbiprofen patch local application
Description: Attach the patch to back pain area 1 piece per day with no more than 6 hours.
Study NCT04839159 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Blood sampling at the age of 6 and 12 months, 2-3-4 years
Study NCT05240872 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PRP injection
Description: Plantar fascia injection therapy with PRP
Study NCT05240872 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ABI injection
Description: ABI injection
Study NCT00976521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abciximab local infusion
Description: Local infusion of abciximab using the ClearWay™ RX Infusion Catheter
Study NCT00976521 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No local infusion
Description: Intervention without local infusion
Study NCT00976521 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thrombus aspiration
Description: Thrombus aspiration
Study NCT00976521 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thrombus aspiration
Description: Thrombus aspiration
Study NCT01306682 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent influenza vaccine
Description: 0.5 ml of trivalent influenza vaccine administered into deltoid muscle of non dominant arm
Study NCT01306682 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 0.5ml normal saline administered into deltoid muscle of non dominant arm
Study NCT05756062 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Highly-concentrated DHA triglyceride (Tridocosahexanoin-AOX 70%)
Description: Daily administration of 2 capsules of the study product (1000 mg DHA triglyceride) for 3 months
Study NCT02155166 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intracervical anesthesia with lidocaine 2%
Description: 5 min before LNG-IUS placemen
Study NCT02155166 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ibuprofen 400 mg
Description: 1 hour prior to the LNG-IUS insertion
Study NCT01712529 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised physical exercise
Description: Women with systemic lupus erythematosus with availability to perform physical exercise were allocated in exercise group (EG) to practice supervised physical exercise for one hour, three times a week for 16 weeks. Those who were not available for this activity were allocated in the control group (CG). Intervention consisted of walking at speed of the ventilatory threshold-1 heart rate obtained from cardiopulmonary exercise test and monitored by frequency meter.
Study NCT01159665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ocriplasmin
Description: 125µg ocriplasmin intravitreal injection
Study NCT03489811 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Essential Oil Blend
Description: The active essential oil blend consists of plant derived oils which have been distilled from crude plant matter and analyzed in a laboratory to identify chemical composition.
Study NCT03489811 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Blend
Description: The control blend consists of inert vegetable oils which are produced from plant matter.
Study NCT02224755 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HeartMate 3 LVAS
Description: Implantation of HeartMate 3 LVAD to evaluate the safety and effectiveness of the HeartMate 3 LVAS by demonstrating non-inferiority to the HMII LVAS (HMII) when used for the treatment of advanced, refractory, left ventricular heart failure
Study NCT02224755 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HeartMate II LVAS
Description: Implantation of the commercially approved HeartMate II LVAD which is the standard treatment for advanced heart failure
Study NCT03086226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosravuconazole
Description: Fosravuconazole will be given in two arms either as 300mg or 200mg. The drop-the loser design adaptive clinical trial design will allow two stages of the trial separated by a data based decision. In the first stage a decision will be taken on which arm to drop either the Fosravuconazole 200 or the Fosravuconazole 300 arm. The best treatment will be compared against the standard of care, itraconazole. At the end the focus will be comparing the best treatment against standard of care.
Study NCT03995355 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 9618X investigational lipid eye drops
Description: Test Eye Drops
Study NCT03995355 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Blink® Tears
Description: Control Eye Drops
Study NCT01257607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIM-D3 Ophthalmic Solution
Description: 28 Days, BID
Study NCT01257607 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Ophthalmic Solution
Description: 28 Days, BID
Study NCT03474783 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health education
Description: Stages of change of intentions to cease smoking of participants at the baseline were determined, and a personal-tailored health education was accordingly delivered.
Study NCT00494507 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dichlorphenamide (double-blind)
Description: 50mg tablet; maximum dosage 400mg/day
Study NCT03632915 — intervention group
Intervention type: DRUG
Intervention: Phenobarbital
Description: Standard of care
Study NCT03632915 — intervention group
Intervention type: DRUG
Intervention: Ketamine
Description: Standard of care
Study NCT00494507 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (double-blind)
Description: Inactive substance manufactured to look like Dichlorphenamide 50mg tablet
Study NCT00494507 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dichlorphenamide (open-label)
Description: 50mg tablet; maximum dosage 400mg/day
Study NCT00494507 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dichlorphenamide (open-label)
Description: 50mg tablet; maximum dosage 400mg/day
Study NCT04545710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Abemaciclib 150mg BID
Study NCT04545710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Osimertinib 80mg daily
Study NCT01433094 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Falloon et al. Psychoeducation Program
Description: The intervention aims to improve communication and problem-solving abilities in patients and their families by sessions focused on: assessment of the individual's and the family's strengths, weaknesses, and goals; education about schizophrenia and treatment; communication skills training; problem-solving training; and special problems (Falloon et al. 1985). Treatment sessions are provided on a weekly basis for months (1 hour for each session) (groups of about 8-9 persons - patients and caregivers).
Study NCT01433094 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Generic Treatment
Description: The comparator is a treatment with generic informative prospect on the disorders and with the same frequencies as the Intervention. Treatment sessions are provided on a weekly basis for 6 months (1 hour for each session) (groups of about 8-9 persons - patients and caregivers).
Study NCT03632915 — intervention group
Intervention type: DRUG
Intervention: Valproic Acid
Description: Standard of care
Study NCT03086226 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Itraconazole
Description: This will be the active comparator
Study NCT00945932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW870086X
Description: Investigational product
Study NCT00945932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo control
Study NCT04298632 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safety Education Program
Description: this is a pesticide safety education program
Study NCT02358512 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enteral feeding
Description: Bolus feeds or continuous feeds during a 10-day ICU stay
Study NCT02358512 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enteral feeding
Description: Bolus feeds or continuous feeds during a 10-day ICU stay
Study NCT02412917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FV-100
Description: antiviral nucleoside analog
Study NCT02412917 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valacyclovir
Description: antiviral nucleoside analog
Study NCT05506293 — intervention group
Intervention type: PROCEDURE
Intervention: percutaneous paravalvular leak closure
Description: the procedure consists of deployment of an occluder or a vascular plug within the cardiac paravalvular leak. The device is inserted percutaneously from a femoral vascular approach or from a trans-apical approach. The device is deployed through a delivery sheath within the leak. Stability and efficacy to occlude the leak are assessed by transoesophageal echocardiography prior to device release.~Type of devices to be inserted varied :~* Amplatzer vascular plug 3~* occlutech paravalvular leak device~* amplatzer vascular plug 2~* amplatzer muscular ventricular septal defect~* amplatzer vascular plug 4~Devices to be implanted are under the responsability of the local investigator and are not based on the study design.
Study NCT00980031 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eplerenone
Description: 25mg PO daily (QD)for 6 months
Study NCT00980031 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lactose Tablet
Description: Lactose tablet
Study NCT04110730 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D Printed Upper-limb Prosthesis
Description: The fingers and thumb were made of polylactic acid polymer manufactured using industrial 3D printers. The palm, socket, forearm brace, and leveraging structure were made of polylactic acid which has properties similar to thermoplastic that facilitate post manufacturing adjustments. Elastic cords placed inside the dorsal aspect of the fingers provided passive finger extension. Finger flexion was driven by non-elastic cords along the palmar surface of each finger and was activated through 20-30 degrees of wrist or elbow flexion.
Study NCT04110730 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Intervention
Description: An occupational therapy student will perform 3 home visits a week and will direct a training protocol that consists of completing three trials of a series of 6 block building activities (i.e., block-stacking) for each hand separated by 30 seconds of rest (a total of 18 block building activities per hand). The block stacking activity consists in building a 4 block train, 3 cube bridge, 4 block wall, 3 block tower, 6 block steps, and 6 block pyramid. All subjects including the control group will perform the same home training protocol.
Study NCT04110730 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home Intervention
Description: An occupational therapy student will perform 3 home visits a week and will direct a training protocol that consists of completing three trials of a series of 6 block building activities (i.e., block-stacking) for each hand separated by 30 seconds of rest (a total of 18 block building activities per hand). The block stacking activity consists in building a 4 block train, 3 cube bridge, 4 block wall, 3 block tower, 6 block steps, and 6 block pyramid. All subjects including the control group will perform the same home training protocol.
Study NCT02074280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifaximin
Description: Rifaximin is an antibiotic that is virtually non-absorbed after oral administration and exhibits broad spectrum antimicrobial activity against both aerobic and anaerobic gram-positive and gram-negative microorganisms within the gastrointestinal tract.
Study NCT01668914 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IM-SLNB
Description: IM-SLNB is performed according to the pre-operative lymphoscintigraphy
Study NCT01668914 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 99mTc-SC
Description: Two syringes of 0.25\~0.5 mCi 99mTc-SC in 0.2\~1.0 mL volume were injected intraparenchymally into 2 quadrants of breast, at the 6 and 12 o'clock positions.
Study NCT01668914 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Histologic Examination
Description: All IMSLNs were analyzed by histologic examination for future therapy planning.
Study NCT01668914 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LSG
Description: lymphoscintigraphy was performed 0.5\~1.0 hour before surgery
Study NCT01668914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylthioninium
Description: Four milliliters of methylthioninium was injected intraparenchymally around the primary tumor 10 min before surgery
Study NCT03146104 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Intraoperative anesthesia will be maintained using propofol 100-150 mcg/kg/min, oxygen and air and FiO2 of 40% in propofol group (GROUP P)
Study NCT00348686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan
Description: 16 mg once daily in oral tablet form
Study NCT03146104 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoflurane
Description: in(GROUP I) maintenance will be done with 1 MAC of isoflurane, oxygen and air and FiO2 of 40%.
Study NCT06583057 — intervention group
Intervention type: PROCEDURE
Intervention: Thermal ablation
Description: Patients who underwent thermal ablation were performed in the outpatient clinic's operating room under local anesthesia. Thermal ablation was performed under real-time ultrasound-guided. The 18-G bipolar radiofrequency applicator with a 0.9 cm active tip (CelonProSurge micro 100-T09, Olympus Surgical Technologies Europe) , or a 16-G/17-G cooled microwave antenna with a 0.3 cm tip (ECO-100A1, YIGAO MWA system Co., Ltd; KY-2000, Kangyou Medical, Nanjing, China) was used during ablation.
Study NCT03098745 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Omafilcon A
Description: contact lens
Study NCT03098745 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Somofilcon A
Description: contact lens
Study NCT03098745 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Omafilcon A - Proclear (PC)
Description: contact lens
Study NCT03178669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cobitolimod
Description: Rectal administration
Study NCT03178669 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution manufactured to mimic cobitolimod
Study NCT03876665 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT02953886 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silver Diamine Fluoride (SDF)
Description: No caries removal will take place. Bacterial samples will be collected using Gracey curettes at the initial visit before application of SDF and one month after. The tooth will be dried and SDF will be placed on the carious dentin until saturated. Excess will be blotted dry with a cotton pellet
Study NCT00520260 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bromfenac
Description: 0.09%, BID, 6 weeks
Study NCT00520260 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketorolac
Description: 0.4%, BID, 6 weeks
Study NCT00908102 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate
Description: A two level active intervention with a control group was executed for patients suffering from non-acute, moderate LBP in occupational health. Patients were selected by using a self-administered postal questionnaire.
Study NCT00908102 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mild
Description: A one level intervention with long-term effectiveness and cost-effectiveness was executed for patients suffering from non-acute mild level LBP in occupational health. Patients were selected by using a self-administered postal questionnaire.
Study NCT00908102 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mild
Description: A one level intervention with long-term effectiveness and cost-effectiveness was executed for patients suffering from non-acute mild level LBP in occupational health. Patients were selected by using a self-administered postal questionnaire.
Study NCT00908102 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mild vs. NC
Description: A two level intervention with long-term effectiveness and cost-effectiveness was executed for patients suffering from non-acute mild level LBP in occupational health. Intervention arms were compared to NC - no intervention group.
Study NCT00348686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan
Description: 32 mg once daily in oral tablet form
Study NCT00348686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Felodipine
Description: 5 mg once daily in oral tablet form
Study NCT00908102 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mild vs. NC
Description: A two level intervention with long-term effectiveness and cost-effectiveness was executed for patients suffering from non-acute mild level LBP in occupational health. Intervention arms were compared to NC - no intervention group.
Study NCT00908102 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Mild vs. NC
Description: A two level intervention with long-term effectiveness and cost-effectiveness was executed for patients suffering from non-acute mild level LBP in occupational health. Intervention arms were compared to NC - no intervention group.
Study NCT04022707 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-speed circuit resistance training
Description: The program will include three circuits of 11 exercises that target the upper and lower body. Training will gradually increase over the first three week from 1 to 3 circuits.
Study NCT04022707 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational control
Description: Lectures on health and fitness
Study NCT00908102 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate vs. NC
Description: A three level intervention with two control groups was executed for patients suffering from non-acute, moderate LBP in occupational health. RCT intervention groups were compared to NC group - i.e. no intervention.
Study NCT01061658 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live Attenuated Tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus Vaccine
Description: Higher dosage of vaccine
Study NCT00908102 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Moderate vs. NC
Description: A three level intervention with two control groups was executed for patients suffering from non-acute, moderate LBP in occupational health. RCT intervention groups were compared to NC group - i.e. no intervention.
Study NCT00084487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: becatecarin
Description: Given IV
Study NCT01978444 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic D2 lymphadenectomy plus CME
Study NCT01978444 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic D2 lymphadenectomy